Introduction
============

Neuroblastoma is an extracranial solid tumor of the developing sympathetic nervous system \[[@r1],[@r2]\]. This disease is the most common cancer in children under age of 1 year old, and accounts for about 7% of all childhood malignancies \[[@r2]\]. The prognosis of neuroblastoma varies greatly from spontaneous regression without chemotherapy to aggressive, incurable disease \[[@r3],[@r4]\]. Approximately, 50% of affected children are diagnosed with a localized low- or intermediate- risk disease while rest of patients are of metastatic high-risk neuroblastomas \[[@r4]--[@r6]\]. The long-term survival rates of high-risk neuroblastoma cases remain disappointingly low despite of great advances in treatments \[[@r6]--[@r8]\].

The etiology of neuroblastoma is not fully elucidated \[[@r4]\]. Previous evidence has suggested that environmental risk factors for neuroblastoma, but no direct linkage is established in between \[[@r9],[@r10]\]. Neuroblastoma is characterized by genomic instability and chromosomal abnormalities. Growing evidence indicated that the carcinogenesis of neuroblastoma is also partially attributed to the genetic factors and the gene-environment interactions. For instance, amplification of *MYCN* is observed in approximately 20% of neuroblastoma cases and associated with poor prognosis \[[@r11]\], and *ALK* mutation is identified in nearly 1% of neuroblastoma cases \[[@r12],[@r13]\]. Recently, genome-wide association studies (GWASs) identified several neuroblastoma susceptibility loci \[[@r14]--[@r19]\]. Candidate gene approaches and fine mapping analysis also revealed that genetic variants in the *NEFL* \[[@r20]\], *CNKN1B* \[[@r21]\], and *BARD1* gene \[[@r22]\] are associated with neuroblastoma susceptibility.

*X-ray repair cross-complementing group 1* (*XRCC1*) was the first identified mammalian gene that is involved in the single strand DNA break repair \[[@r23]\]. XRCC1 serves as the scaffold protein without catalytic activity; alternatively, it facilitates single strand DNA break repair by cooperating with other proteins such as DNA polymerase β and DNA ligase III \[[@r24]--[@r26]\]. XRCC1 is mainly responsible for repairing DNA damage caused by ionizing radiation, alkylation, and UV exposure \[[@r27]--[@r29]\]. The abnormal function of XRCC1 protein could cause human cells more vulnerable to ionizing radiation and DNA-damaging agents. The associations between *XRCC1* polymorphisms and the risk of cancer have been widely investigated, including lung cancer \[[@r30]\], gastric cancer \[[@r31]\], and colorectal cancer \[[@r32]\]. However, no such association study has been performed in neuroblastoma. Give the significant role of XRCC1 in DNA repair, we conducted a case-control study to explore the association between *XRCC1* polymorphisms and risk of neuroblastoma.

RESULTS
=======

*XRCC1* gene polymorphisms and neuroblastoma susceptibility
-----------------------------------------------------------

The characteristics of participants were described in our previous studies ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) \[[@r33]--[@r36]\]. The genotype frequencies of the four *XRCC1* polymorphisms (rs1799782 G\>A, rs25487 C\>T, rs25489 C\>T and rs915927 T\>C) in the neuroblastoma cases and controls are presented in [Table 1](#t1){ref-type="table"}. In the single locus analysis, none of the analyzed polymorphism was significantly associated with neuroblastoma risk. In analyzing the combined effect of risk genotypes, we found that subjects carrying 2 risk genotypes had a significantly increased neuroblastoma risk at an adjusted odds ratio (OR) of 1.69 \[95% confidence interval (CI)=1.06-2.69\] when compared with those carrying 0 risk genotype.

###### Association between *XRCC1* gene polymorphisms and neuroblastoma susceptibility.

  --------------------------------------- ------------- ------------- --------- ---------------------- ----------- ---------------------- -----------
  Genotype                                Cases\        Controls\     *P* ^a^   Crude OR\              *P*         Adjusted OR\           *P* ^b^
                                          (N=393)       (N=812)                 (95% CI)                           (95% CI) ^b^           

  rs1799782 G\>A                                                                                                                          

  GG                                      182 (46.31)   406 (50.00)             1.00                               1.00                   

  GA                                      177 (45.04)   333 (41.01)             1.19 (0.92-1.53)       0.186       1.19 (0.92-1.53)       0.187

  AA                                      34 (8.65)     73 (8.99)               1.04 (0.67-1.62)       0.866       1.04 (0.67-1.62)       0.872

  Additive                                                            0.409     1.08 (0.90-1.30)       0.399       1.08 (0.90-1.30)       0.402

  Dominant                                211 (53.69)   406 (50.00)   0.230     1.16 (0.91-1.48)       0.230       1.16 (0.91-1.48)       0.231

  Recessive                               359 (91.35)   739 (91.01)   0.846     0.96 (0.63-1.47)       0.847       0.96 (0.63-1.47)       0.841

  rs25487 C\>T                                                                                                                            

  CC                                      221 (56.23)   471 (58.00)             1.00                               1.00                   

  CT                                      151 (38.42)   278 (34.24)             1.16 (0.90-1.49)       0.260       1.16 (0.90-1.50)       0.257

  TT                                      21 (5.34)     63 (7.76)               0.71 (0.42-1.19)       0.197       0.71 (0.42-1.20)       0.199

  Additive                                                            0.160     0.98 (0.81-1.19)       0.867       0.98 (0.81-1.20)       0.874

  Dominant                                172 (43.77)   341 (42.00)   0.560     1.08 (0.84-1.37)       0.560       1.08 (0.84-1.37)       0.554

  Recessive                               372 (94.66)   749 (92.24)   0.123     0.67 (0.40-1.12)       0.125       0.67 (0.40-1.12)       0.126

  rs25489 C\>T                                                                                                                            

  CC                                      326 (82.95)   636 (78.33)             1.00                               1.00                   

  CT                                      64 (16.28)    170 (20.94)             0.73 (0.54-1.01)       0.056       0.73 (0.53-1.01)       0.055

  TT                                      3 (0.76)      6 (0.74)                0.98 (0.24-3.93)       0.972       0.99 (0.25-4.01)       0.994

  Additive                                                            0.160     0.77 (0.57-1.03)       0.079       0.77 (0.57-1.03)       0.078

  Dominant                                67 (17.05)    176 (21.67)   0.061     0.74 (0.54-1.01)       0.061       0.74 (0.54-1.01)       0.060

  Recessive                               390 (99.24)   806 (99.26)   0.963     1.03 (0.26-4.15)       0.963       1.05 (0.26-4.24)       0.942

  rs915927 T\>C                                                                                                                           

  TT                                      294 (74.81)   627 (77.22)             1.00                               1.00                   

  TC                                      97 (24.68)    169 (20.81)             1.22 (0.92-1.63)       0.165       1.23 (0.92-1.64)       0.158

  CC                                      2 (0.51)      16 (1.97)               0.27 (0.06-1.17)       0.079       0.27 (0.06-1.16)       0.078

  Additive                                                            0.056     1.04 (0.81-1.35)       0.740       1.05 (0.81-1.35)       0.729

  Dominant                                99 (25.19)    185 (22.78)   0.356     1.14 (0.86-1.51)       0.356       1.15 (0.86-1.52)       0.345

  Recessive                               391 (99.49)   796 (98.03)   0.050     0.26 (0.06-1.11)       0.069       0.25 (0.06-1.11)       0.068

  Combined effect of risk genotypes ^c^                                                                                                   

  0                                       31 (7.89)     90 (11.08)              1.00                               1.00                   

  1                                       240 (61.07)   509 (62.68)             1.37 (0.89-2.12)       0.158       1.38 (0.89-2.13)       0.150

  2                                       121 (30.79)   210 (25.86)             **1.67 (1.05-2.66)**   **0.030**   **1.69 (1.06-2.69)**   **0.028**

  3                                       1 (0.25)      3 (0.37)                0.97 (0.10-9.65)       0.978       0.96 (0.10-9.54)       0.969

  Trend                                                               0.154     **1.25 (1.02-1.53)**   **0.032**   **1.25 (1.02-1.54)**   **0.030**

  0-1                                     271 (68.96)   599 (73.77)             1.00                               1.00                   

  2-3                                     122 (31.04)   213 (26.23)   0.081     1.27 (0.97-1.65)       0.081       1.27 (0.97-1.65)       0.078
  --------------------------------------- ------------- ------------- --------- ---------------------- ----------- ---------------------- -----------

OR: odds ratio; CI: confidence interval. ^a^ *χ^2^* test for genotype distributions between neuroblastoma patients and controls. ^b^ Adjusted for age and gender. ^c^ The risk genotypes were rs1799782 GA/AA, rs25487 CT/TT, rs25489 TT and rs915927 TC/CC.

Stratification analysis
-----------------------

We then further conducted stratification analysis for rs25489 C\>T by age, gender, tumor sites of origin and clinical stages ([Table 2](#t2){ref-type="table"}). Compared to the rs25489 CC genotype, the protective effect of CT/TT genotypes was more predominant for children ≤ 18 months of age (adjusted OR=0.54; 95% CI=0.31-0.95) and those with clinical stage I+II+4s disease (adjusted OR=0.53, 95% CI=0.33-0.87). With the 0-1 risk genotypes as the reference group, the presence of 2-3 risk genotypes was associated with an elevated neuroblastoma risk among children ≤ 18 months of age (adjusted OR=1.87; 95% CI=1.19-2.93) and those with clinical stage I+II+4s tumor (adjusted OR=1.56, 95% CI=1.09-2.23).

###### Stratification analysis of *XRCC1* rs25489 C\>T polymorphism and combined risk genotypes with neuroblastoma susceptibility.

  ----------------- ------------------ --------------- ----------------- ----------------- ----------------- ------------------ ------------- -------- ----------------- ----------- ----------------- -----------
  Variables         rs25489\           OR (95% CI)     *P*               AOR(95% CI) ^a^   *P* ^a^           Combined\          OR (95% CI)   *P*      AOR (95% CI)^a^   *P* ^a^                       
                    (cases/controls)                                                                         (cases/controls)                                                                          

                    CC                 CT/TT                                                                                    0-1           2-3                                                      

  Age, month                                                                                                                                                                                           

  ≤18               108/233\           18/72\          **0.54**\         **0.032**         **0.54**\         **0.032**          81/235        45/70    **1.87**\         **0.007**   **1.87**\         **0.007**
                    (27.48/28.69)      (4.58/8.87)     **(0.31-0.95)**                     **(0.31-0.95)**                                             **(1.19-2.93)**               **(1.19-2.93)**   

  \>18              218/403\           49/104\         0.87\             0.473             0.87\             0.469              190/364       77/143   1.03\             0.852       1.03\             0.851
                    (55.47/49.63)      (12.47/12.81)   (0.60-1.27)                         (0.60-1.27)                                                 (0.74-1.43)                   (0.74-1.43)       

  Gender                                                                                                                                                                                               

  Females           141/262\           27/80\          0.63\             0.058             0.63\             0.058              115/252       53/90    1.29\             0.217       1.28\             0.227
                    (35.88/32.27)      (6.87/9.85)     (0.39-1.02)                         (0.39-1.02)                                                 (0.86-1.93)                   (0.86-1.93)       

  Males             185/374\           40/96\          0.84\             0.411             0.84\             0.402              156/347       69/123   1.25\             0.215       1.25\             0.206
                    (47.07/46.06)      (10.18/11.82)   (0.56-1.27)                         (0.56-1.26)                                                 (0.88-1.77)                   (0.88-1.78)       

  Sites of origin                                                                                                                                                                                      

  Adrenal gland     127/636\           26/176\         0.74\             0.193             0.73\             0.183              107/599       46/213   1.21\             0.327       1.22\             0.313
                    (32.31/78.32)      (6.62/21.67)    (0.47-1.17)                         (0.47-1.16)                                                 (0.83-1.77)                   (0.83-1.78)       

  Retroperitoneal   74/636\            13/176\         0.64\             0.146             0.64\             0.151              60/599        27/213   1.27\             0.337       1.27\             0.332
                    (18.83/78.32)      (3.31/21.67)    (0.34-1.17)                         (0.35-1.18)                                                 (0.78-2.05)                   (0.78-2.05)       

  Mediastinum       90/636\            19/176\         0.76\             0.310             0.75\             0.282              75/599        34/213   1.28\             0.273       1.28\             0.265
                    (22.90/78.32)      (4.83/21.67)    (0.45-1.29)                         (0.45-1.27)                                                 (0.83-1.97)                   (0.83-1.98)       

  Others            27/636\            9/176\          1.21\             0.637             1.21\             0.636              23/599        13/213   1.59\             0.193       1.60\             0.189
                    (6.87/78.32)       (2.29/21.67)    (0.56-2.61)                         (0.56-2.62)                                                 (0.79-3.19)                   (0.80-3.21)       

  Clinical stages                                                                                                                                                                                      

  I+II+4s           141/636\           21/176\         **0.54**\         **0.013**         **0.53**\         **0.011**          104/599       58/213   **1.57**\         **0.014**   **1.56**\         **0.015**
                    (35.88/78.32)      (5.34/21.67)    **(0.33-0.88)**                     **(0.33-0.87)**                                             **(1.10-2.24)**               **(1.09-2.23)**   

  III+IV            168/636\           43/176\         0.93\             0.683             0.93\             0.698              154/599       57/213   1.04\             0.817       1.04\             0.823
                    (42.75/78.32)      (10.94/21.67)   (0.64-1.35)                         (0.64-1.35)                                                 (0.74-1.47)                   (0.74-1.47)       
  ----------------- ------------------ --------------- ----------------- ----------------- ----------------- ------------------ ------------- -------- ----------------- ----------- ----------------- -----------

AOR: adjusted odds ratio; CI: confidence interval. ^a^ Adjusted for age and gender in logistic regress models, without the corresponding stratify factor.

DISCUSSION
==========

In this two-center Chinese population study, we examined the impact of polymorphisms in the *XRCC1* gene on neuroblastoma susceptibility. We found that *XRCC1* polymorphisms might play a low-penetrant role on the neuroblastoma risk.

*XRCC1* gene is located on chromosome 19q13.2 and encodes a 633 amino acid protein \[[@r37]\]. It consists of 17 exons, spanning a genomic distance of 32 kb. By now, more than 8,453 polymorphisms in the *XRCC1* have been identified. Among them, three common polymorphisms, rs25487 C\>T (Arg399Gln), rs25489 C\>T (Arg280His), and rs1799782 G\>A (Arg194Trp), are mostly investigated. These three polymorphisms could cause amino acid changes in evolutionarily conserved regions \[[@r23],[@r38]\], and may further lead to the alteration in the XRCC1 protein activity. Previous study showed that *XRCC1* polymorphism 399Gln allele might affect the function of XRCC1 protein, consequently impairing DNA repair capacity \[[@r39]\].

Increasing epidemiological studies have been performed regarding the association between *XRCC1* polymorphisms and cancer risk. Hong et al. observed that rs25487 T allele and the 3 common allele combinations (rs25487 C\>T, rs25489 C\>T, and rs1799782 G\>A) were associated with an increased risk of colorectal cancer in a study of 209 colorectal cancer cases and 209 controls recruited from Korean \[[@r40]\]. Divine et al. reported that *XRCC1* rs25487 TT genotype conferred susceptibility to lung adenocarcinoma at an OR of 2.8 (95% CI=1.2-7.9) in a case-control study \[[@r41]\]. In a population-based case-control study conducted among Korean population, Lee et al. found that none of the polymorphisms (rs25487 C\>T, rs25489 C\>T, and rs1799782 G\>A) contributed to the risk of gastric cancer \[[@r42]\]. Duellet al. also reported a null association between *XRCC1* rs1799782 G\>A and breast cancer risk in a population-based case-control study in North Carolina \[[@r43]\]. However, they observed a positive association for rs25487 CT or TT genotypes compared with CC among African Americans, but not Caucasians. This conflicting role of *XRCC1* polymorphisms indicates their risk effects may depend on cancer types and ethnic groups.

In the present study, we found that none of the four polymorphisms of *XRCC1* gene were associated with the risk of neuroblastoma. Failure to detect the association between *XRCC1* polymorphisms and neuroblastoma risk might be due to the small sample size and the low-penetrant effect of common polymorphisms. In the combined analysis, subjects carrying 2 risk genotypes tend to have increased neuroblastoma risk, when those without risk genotypes serve as a reference. Stratification analysis revealed that the rs25489 CT/TT is associated with favorable clinical markers such as ≤ 18 months of age and clinical stage I+II+4s. While exploring cumulative effects of risk genotypes, we found that the presence of 2-3 risk genotypes was associated with neuroblastoma risk among children ≤ 18 months of age and those with clinical stage I+II+4s tumors. It is believed that cancer susceptibility results from interactions of genetic and environmental factors and is subjected to modification of clinical markers such as age and clinical stage; in other words, the effect of one SNP on cancer susceptibility maybe modified by other genetic variants, environment exposures, and clinical makers. Single-locus analysis in the current study only focused on one genetic factor. the rs25489. Stratified analysis by age and clinical stage involve the effects of the rs25489 and clinical makers. While SNPs were combined, stratified analysis by age and clinical stage involve interaction of multiple SNPs and clinical makers. It is reasonable that analyses involved in different variables may lead to different results. Therefore, results considering interplays of gene-gene, gene-environmental factors and clinical makers maybe more meaningful in the clinical setting. Alternatively, these results could be chance findings, which calls for larger validation studies.

The study was limited by several points. Firstly, the relative small number of participants in the study impaired the statistical power. Therefore, the null association obtained in this study should be cautiously explained. Secondly, the insufficient information about environmental factors limited our ability to analyze gene-environment interactions. Thirdly, only four polymorphisms were investigated in the current study. More polymorphisms should be tested in the future work. Fourthly, due to the restriction to Chinese descent, these findings cannot be directly extrapolated to other ethnicities before validation studies. Last, our work lacks of *in vitro* data to support a role for these *XRCC1* polymorphisms in neuroblastoma, which should be completed in the future.

In conclusion, we report that polymorphisms in *XRCC1* gene may exert a low-penetrant effect on neuroblastoma risk in Chinese population. Our study helps to provide novel insight into the role of *XRCC1* gene polymorphisms in neuroblastoma risk. The findings should be further confirmed in other independent case-control studies.

MATERIALS AND METHODS
=====================

Study populations
-----------------

Details of the selection criteria and characteristics of the study participants were provided elsewhere \[[@r33]--[@r36]\]. In brief, 393 neuroblastoma cases and 812 healthy controls were included in this study. The cases were from two medical centers, Guangzhou Women and Children's Medical Center and the First Affiliated Hospital of Zhengzhou University. All the controls were selected from the same region as cases during the same period. Informed consent was obtained at the time of enrollment. This study was conducted under the approval of the Institutional Review Board of the participating hospitals.

Polymorphism selection
----------------------

Potentially functional polymorphisms in the *XRCC1* gene were selected using dbSNP database (<http://www.ncbi.nlm.nih.gov/>) and SNPinfo (<http://snpinfo.niehs.nih.gov/>) \[[@r44]\]. In final, four polymorphisms: rs1799782 G\>A, rs25487 C\>T, rs25489 C\>T and rs915927 T\>C, were adopted for analysis. As shown in our [Supplementary Figure 1](#SD2){ref-type="supplementary-material"}, there was no significant LD (R^2^\<0.8) among these SNPs of *XRCC1* (R^2^=0.032 between rs25487 and rs25489, R^2^=0.039 between rs25487 and rs915927, R^2^=0.122 between rs25487 and rs1799782; R^2^=0.014 between rs25489 and rs915927, R^2^=0.043 between rs25489 and rs1799782, R^2^=0.046 between rs915927 and rs1799782).

Genotyping
----------

We used a TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China) for DNA extraction. Polymorphisms were genotyped applying TaqMan platform (Applied Biosystem, Foster City, CA, USA) without knowing the status of the participants \[[@r45]--[@r47]\]. Quality control was conducted by including eight negative controls with water in each plate. We also randomly selected 10% of the samples to perform a second genotyping, and the concordance rate was 100%.

Statistical analysis
--------------------

The Hardy-Weinberg equilibrium (HWE) was performed for each polymorphism among controls using the goodness-of-fit χ^2^ test. Two-sided chi-square test was applied to compare the demographic variables between the case group and controls. Tests for association between *XRCC1* polymorphisms and neuroblastoma risk were conducted by comparing the genotype frequencies between cases and controls using the χ^2^ test. We also applied stratified analyses by age, gender, tumor sites, and clinical stages. All analyses were conducted with SAS release 9.4 (SAS Institute, Cary, NC). *P*\< 0.05 was defined as statistically significant.
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